HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A
Not Applicable
Recruiting
- Conditions
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A
- Registration Number
- JPRN-UMIN000048156
- Lead Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main survey items etc. 1) Information on facilities 2) Patient demographics 3) Prior treatment history 4) Administration status of HEMLIBRA 5) Factor eight activity and factor eight inhibitor titer prior to HEMLIBRA treatment 6) Factor eight activity and factor eight inhibitor titer after the start of HEMLIBRA 7) APTT measurement or not 8) Concomitant drugs (containing prior treatment), immunosuppressive therapy 9) Combination therapy 10) Adverse events
- Secondary Outcome Measures
Name Time Method